The studies summarized below are presented with these contextual limitations made explicit
Using research-grade products intended for laboratory work exposes users to unnecessary risks including contamination, incorrect dosing, and potential adverse reactions
Wong ML, Inserra A, Lewis MD, Mastronardi CA, Leong L, Choo J, et al
Strengths and Limitations Strengths of our consensus report and the associated recommendations include the participation of an international panel of experts in GLP-1 and GLP-1/GIP RA therapies from the United States, Europe, and Asia, along with participation of individuals with lived experience of T1D and using GLP-1 and GLP-1/GIP RA therapy
Weight loss with Semaglutide GLP-1 is usually gradual and steady, with most clients noticing significant improvements over several months